DOI: http://dx.doi.org/10.18203/2349-2902.isj20181389

Pancreatic ductal adenocarcinoma in a Moroccan population: analysis of six years experience

Aziz Bazine, Mohamed Fetohi, Mehdi Tores, Rachid Tanz, Moulay El Hassan Tahiri, Abdelkrim Choho, Mohamed Ichou

Abstract


Background: Few studies have been done to investigate pancreatic cancer in Morocco. Therefore, the aim of our study was to describe the epidemiological, clinical and therapeutic features of pancreatic ductal adenocarcinoma in Moroccan population.

Methods: Author retrospectively reviewed the medical data of pancreatic ductal adenocarcinoma patients presented to the Medical Oncology Department of the Military Hospital Moulay Ismail in Meknes, Morocco, from January 2011 to December 2016.

Results: The study included 67 cases of pancreatic ductal adenocarcinoma. The mean age of patients was 61.24±10.35 years. Male/female ratio was 3.2/1. 20.9% of patients were cigarette smokers, 10.5% alcoholics. 23.9% diabetics, 3.0% with a positive family history of pancreatic cancer and 25.4% with a family history of diabetes mellitus. The main symptoms for consultation were weight loss (68.6%), abdominal pain (64.2%), jaundice (53.7%) and vomiting (25.4%). The tumour was located to the pancreatic head in 71.6% of cases. Stage IV disease was the most common stage representing 47.8% of patients. Biliary and duodenal stent placements were respectively performed in 10.4% and 3.0% of patients. 23.9% of patients underwent curative surgery, 7.5% had palliative surgery and 86.6% received chemotherapy. The median overall survival for the entire cohort was 9.3 months (95% CI 7.2-12.1 months) with a median follow-up of 9.7 months (2-63 months).

Conclusions: The data on pancreatic ductal adenocarcinoma in Moroccan population are similar to the epidemiologic literature data. With multimodality treatments, the results in terms of survival benefit seem to be similar to those in Asian and Caucasian populations.


Keywords


Diagnosis, Epidemiology, Pancreatic neoplasm, Therapeutics

Full Text:

PDF

References


Raissouni S, Rais G, Mrabti H, Raissouni F, Mouzount H, Aitelhaj M, et al. Pancreatic adenocarcinoma in young adults in a moroccan population. J Gastrointest Cancer. 2012;43(4):607-11.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86.

Pourhoseingholi MA, Ashtari S, Hajizadeh N, Fazeli Z, Zali MR. Systematic review of pancreatic cancer epidemiology in Asia-Pacific Region: major patterns in Globacon 2012. Gastroenterol Hepatol Bed Bench. 2017;10(4):245-57.

Stark A, Eibl G. Pancreatic Ductal Adenocarcinoma, 2015. Available at: https://www.pancreapedia.org//reviews/pancreatic-ductal-adenocarcinoma. Accessed 18 February 2018.

Adamska A, Domenichini A, Falasca M. Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies. Int J Mol Sci. 2017;18(7):1338.

Cancer register of Casablanca 2008-2012. Available at: http://www.contrelecancer.ma/site_media/uploaded_files/RCRGC.pdf. Accessed 18 February 2018.

Moumen M, El Alaoui ME, Mokhtari M, El Fares F. Our experience in the treatment of pancreatic head cancer about 146 cases. Médecine Maghreb. 1991;30:33-6.

Faik M, Halhal A, Oudanane M, Housni K, Ahalat M, Baroudi S, et al. Cancer of the pancreas head at the stage of jaundice (about 38 cases). Médecine Maghreb. 1998;72:6-8.

El Malki H, El Mazouz S, El Sayegh H, El Alaoui M, Louchi A, Mdaghri J, et al. Tumors of the head of the pancreas at advanced stages (about 100 cases). Maroc Méd. 2001;23(4):248-52.

Mouaqit O, Alami FE, Chourak M, Ouanani M, Absi ME, Echarrab M, et al. Le cancer de la tête du pancréas vu aux urgences: aspects cliniques et thérapeutiques. Afr J Cancer. 2009;1(4):217-22.

Edge S, Byrd DR, Compton CC, Fritz AG, Greene F, Trotti A, éditeurs. AJCC Cancer Staging Handbook: From the AJCC Cancer Staging Manual. 7th Éd. New York: Springer-Verlag; 2010.

Ilic M, Ilic I. Epidemiology of pancreatic cancer. World J Gastroenterol. 2016;22(44):9694-705.

Midha S, Chawla S, Garg PK. Modifiable and non-modifiable risk factors for pancreatic cancer: A review. Cancer Lett. 2016;381(1):269-77.

Maisonneuve P, Lowenfels AB. Risk factors for pancreatic cancer: a summary review of meta-analytical studies. Int J Epidemiol. Févr. 2015;44(1):186-98.

Dobbins M, Decorby K, Choi BCK. The Association between Obesity and Cancer Risk: A Meta-Analysis of Observational Studies from 1985 to 2011. ISRN Prev Med. 2013;2013:680536.

Wang YT, Gou YW, Jin WW, Xiao M, Fang HY. Association between alcohol intake and the risk of pancreatic cancer: a dose-response meta-analysis of cohort studies. BMC Cancer. 2016;16:212.

Yeo TP. Demographics, epidemiology, and inheritance of pancreatic ductal adenocarcinoma. Semin Oncol. 2015;42(1):8-18.

Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterol. 2013;144(6):1252-61.

Wahi MM, Shah N, Schrock CE, Rosemurgy AS, Goldin SB. Reproductive factors and risk of pancreatic cancer in women: a review of the literature. Ann Epidemiol. 2009;19(2):103-11.

Bosetti C, Rosato V, Li D, Silverman D, Petersen GM, Bracci PM, et al. Diabetes, antidiabetic medications, and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case-Control Consortium. Ann Oncol Off J Eur Soc Med Oncol. 2014;25(10):2065-72.

Midha S, Sreenivas V, Kabra M, Chattopadhyay TK, Joshi YK, Garg PK. Genetically Determined Chronic Pancreatitis but not Alcoholic Pancreatitis Is a Strong Risk Factor for Pancreatic Cancer. Pancreas. 2016;45(10):1478-84.

Ouattara A, Kone S, Soro D, Assi C, Allah-Kouadio E, Bi RIG, et al. Pancreatic Cancer: Epidemiological, Clinical and Therapeutic Aspects in Abidjan (Ivory Coast). Open J Gastroenterol. 2017;7(8):223-9.

Gohar SF, Megahid F, Rizk M, Kasemy ZA, Barsoom TY. Clinical Outcome of Exocrine Pancreatic Adenocarcinoma: A Single Center Experience. Res Oncol. 2017;13(2):33-9.

Tas F, Sen F, Keskin S, Kilic L, Yildiz I. Prognostic factors in metastatic pancreatic cancer: Older patients are associated with reduced overall survival. Mol Clin Oncol. 2013;1(4):788-92.

Al-Majed HT, El-Basmi AA, Al-Mohannadi SH, Govindan R, Rajakumari GB. Pancreatic cancer: Incidence, clinical profile, and frequency of associated factors in Kuwait. Alex J Med. 2013;49(1):75-80.

Coulibaly S, Kéïta K, Sissoko SB, Diallo M, Touré M, Sidibé S. Contribution of ultrasound in the diagnosis of pancreatic tumors in the radiology department of the university hospital center of Point G. J Afr Imag Méd. 2013;3(5):164-72.

Kongkam P, Benjasupattananun P, Taytawat P, Navicharoen P, Sriuranpong V, Vajragupta L, et al. Pancreatic cancer in an Asian population. Endosc Ultrasound. 2015;4(1):56-62.

Sellam F, Harir N, Khaled MB, Mrabent NM, Salah R, Diaf M. Epidemiology and risk factors for exocrine pancreatic cancer in a Northern African population. J Gastrointest Cancer. 2015;46(2):126-30.

AlGhamdi HJ, Alfaifi SA, Alolayan AA, Musaad SMA, Jazieh AM. Pancreatic cancer in Saudi patients treated at tertiary institution. Ten years retrospective study. Saudi Med J. 2013;34(6):604-8.

Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, et al. SEER Cancer Statistics Review 1975-2008 National Cancer Institute SEER Cancer Statistics Review 1975-2008 National Cancer Institute. Bethesda (MD): National Cancer Institute; 2011.

Fest J, Ruiter R, van Rooij FJA, van der Geest LGM, Lemmens VEPP, Ikram MA, et al. Underestimation of pancreatic cancer in the national cancer registry - Reconsidering the incidence and survival rates. Eur J Cancer Oxf Engl. 2017;72:186-91.

Liszka Ł, Pająk J, Mrowiec S, Zielińska-Pająk E, Lampe P, Gołka D. Age distribution patterns of patients with conventional ductal adenocarcinoma of the pancreas. A single-institution study of 580 cases re-evaluated using current histopathological diagnostic criteria. Pol J Pathol. 2010;61(2):65-77.

Worni M, Guller U, White RR, Castleberry AW, Pietrobon R, Cerny T, et al. Modest improvement in overall survival for patients with metastatic pancreatic cancer: a trend analysis using the surveillance, epidemiology, and end results registry from 1988 to 2008. Pancreas. 2013;42(7):1157-63.

Almadi MA, Alharbi O, Azzam N, Altayeb M, Javed M, Alsaif F, et al. Clinical Predictors of Resectability of Pancreatic Adenocarcinoma. Saudi J Gastroenterol. 2013;19(6):278-85.

Bouglouga O, Lawson-Ananissoh LM, Bagny A, Kaaga L, Redah D. Pancreas cancer: epidemiological and clinical studies, and management in the hepato-gastroenterology department of the University Hospital of Lome (Togo). Médecine Santé Trop. 2015;25(3):323-36.

El Guesmi S, Ben Nasr S, Afrit M, Labidi S, Boussen H. Exocrine Pancreatic carcinoma in Tunisia: A retrospective study about 158 cases. Tunis Med. 2015;93(2):73-5.

Lakatos G, Balázs A, Kui B, Gódi S, Szücs Á, Szentesi A, et al. Pancreatic Cancer: Multicenter Prospective Data Collection and Analysis by the Hungarian Pancreatic Study Group. J Gastrointest Liver Dis. 2016;25(2):219-25.

Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. Lancet Lond Engl. 2016;388(10039):73-85.

Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817-25.

Lewis AR, Pihlak R, McNamara MG. The importance of quality of life management in patients with advanced pancreatic ductal adenocarcinoma. Curr Probl Cancer 2018;1:13.